tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['hcc', 'durva']
no surprise durva/tremi increases rates of hypothyroidism and diarrhea compared to durva alone for patients with hcc. imae predicts long-term survival benefit. #asco23 #hcc 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.